Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366845 · ClinicalTrials.gov registry record · Phase 4
Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
A Phase 4 study of Liver Disease, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02366845 is a Phase 4 study of Liver Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 50 participants, below the 792-participant average among 14 other Liver Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02366845, a Phase 4 study of Liver Disease, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to learn more about transfusion of a human blood component called plasma in patients who have liver problems. Patients are asked to be in this study because they have liver disease and therefore may require the transfusion of plasma. The dose of plasma required to reach certain blood clotting laboratory targets is usually determined by clinicians. Due to the complexity of the patient's blood clotting disorder, determining the appropriate dose of plasma is very difficult. The investigators have developed a dosing table based on information from other patients with liver disease and the investigators are testing it to see if it is a more accurate dosing tool then clinician chosen dosing of plasma in patients with liver disease who need one or more plasma transfusions
Conditions Studied
Interventions
- BIOLOGICAL Fresh Frozen Plasma
- DIAGNOSTIC_TEST Pre-Transfusion International Normalized Ratio (INR)
- DIAGNOSTIC_TEST Post-Transfusion International Normalized Ratio (INR)
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-06-27 |
| Est. Completion | 2019-03-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366845
The ClinicalTrials.gov registry entry for NCT02366845 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 792-participant average among 14 other Liver Disease trials with a reported enrollment target (94% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Disease appearing as the primary indexed condition, and to 3 interventions - of which Fresh Frozen Plasma is the first listed.
NCT02366845 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT02366845 about?
NCT02366845 is a clinical study titled "Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease". This study plans to learn more about transfusion of a human blood component called plasma in patients who have liver problems. Patients are asked to be in this study because they have liver disease and therefore may require the transfusion of plasma. The dose of plasma required to reach certain blo...
What is the current status of trial NCT02366845?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2012-06-27. Estimated completion is 2019-03-27.
What conditions does trial NCT02366845 study?
This clinical trial studies the following conditions: Liver Disease.
What interventions are being tested in trial NCT02366845?
The interventions under investigation include: Fresh Frozen Plasma (BIOLOGICAL), Pre-Transfusion International Normalized Ratio (INR) (DIAGNOSTIC_TEST), Post-Transfusion International Normalized Ratio (INR) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02366845?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02366845 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
ACTIVE NOT RECRUITING
-
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
COMPLETED · Phase 2
-
Hepatic Impairment Study
COMPLETED · Phase 1
-
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
COMPLETED
-
Pediatric Liver Database
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.